Nov 9 (Reuters) – Swiss drug developer Windward Bio Group AG is targeting a valuation of up to $1 billion in its US initial public offering, as a strong run for the biotech IPO market extends into
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
(Adds Credit Agricole's Banco BPM merger proposal; updates MPS bids for Banco BPM and Banca…
VIDEO SHOWS: HIGHLIGHTS OF WORLD RECORD ATTEMPT FOR A HUMAN CATAPULT SHOTLIST AND SCRIPT TO…
By Heekyong Yang, Kyu-seok Shim and Tom Westbrook SEOUL/SYDNEY, Nov 9 (Reuters) - Nvidia shares…
Nov 9 (Reuters) - Akamai Technologies Inc: * AKAMAI TECHNOLOGIES - ENTERS AMENDMENT NO. 4…
MOSCOW, Nov 9 (Reuters) - Russia's October exports of wheat, barley and corn are estimated…
VIDEO SHOWS: HIGHLIGHTS OF WORLD RECORD ATTEMPT FOR A HUMAN CATAPULT SHOTLIST AND SCRIPT TO…